[1]Danner SA,Carr A,Leonard JM,et al.A short-term study of the safe-ty,pharmacokinetics,and efficacy of ritonavir,an inhibitor of HIV-1 protease[J].N Engl J Med,1995,333:1528.
[2]Lal R,Hsu A,Chen p,et al.Single dose pharmacokinetics of ABT-378 in combination with ritonavir (abstract).37 th Intersci Conf Antimi-crob Agents Chemother (ICAAC),Toronto,September 28-October 1,1997:279.
[3]Horneff G,Adams O,Wahn V.Preliminary experiences with ritonavir in children with advanced HIV infection[J].Infection,1999,27(2):103107.
[4]Arribase JR,Ibanez C,Ruiz-Antoran B,et al.Acute hepatitis in HIV-infected patients during ritonavir treatment[J].AIDS,1998,12(13):1722.
[5]Benveniste O,Longuet P,Duval X,et al.Two episodes of acute renal failure,rhabdomyolysis,and severe hepatitis in an AIDS patient succe-sively treated with ritonavir and indinavir[J].Clin Infect Dis,1999,28:1180.
[6]Blanche P,Rigolet A,Gombert B,et al.Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir[J].Postgrad Med J,1999,75(887):546.